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Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common inherited disorder of mitochondrial
fatty acid b-oxidation in humans. To better understand the pathogenesis of this disease, we developed a mouse model
for MCAD deficiency (MCAD/) by gene targeting in embryonic stem (ES) cells. The MCAD/ mice developed an
organic aciduria and fatty liver, and showed profound cold intolerance at 4 8C with prior fasting. The sporadic cardiac
lesions seen in MCAD/ mice have not been reported in human MCAD patients. There was significant neonatal
mortality of MCAD/ pups demonstrating similarities to patterns of clinical episodes and mortality in MCAD-deficient
patients. The MCAD-deficient mouse reproduced important aspects of human MCAD deficiency and is a valuable model
for further analysis of the roles of fatty acid oxidation and pathogenesis of human diseases involving fatty acid
oxidation.
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Introduction
Mitochondrial b-oxidation of fatty acids provides energy,
especially during fasting conditions. Fatty acid oxidation
occurs in mitochondria and consists of a repeating circuit of
four sequential steps. There are four straight-chain acyl-CoA
dehydrogenases involved in the initial step. Medium-chain
acyl-CoA dehydrogenase (MCAD) (the mouse gene is Acadm,
whereas the protein is MCAD), specifically, is responsible for
catalyzing the dehydrogenation of medium-chain length (C6–
C12) fatty acid thioesters [1]. Acadm is transcribed in the
nucleus, translated in the cytosol, and translocated into the
mitochondrial matrix [2–4]. Once inside the mitochondrial
matrix, the MCAD monomers are assembled into homo-
tetramers to gain enzymatic activity [4].
MCAD activity is essential for complete fatty acid oxida-
tion. Inherited MCAD deficiency exists in humans as an
autosomal recessive disorder. MCAD deficiency was first
described in 1982—1983 [5–7] and has been described in
numerous patients [1,8–11]. The carrier frequency in the
Caucasian population has been estimated to be between 1 in
50 to 80 with an incidence of clinical disease expected at
around 1 in 15,000 [1,9,12].
MCAD-deficient patients exhibit clinical episodes often
associated with fasting. Patients manifest disease usually
during the first two years of life. Symptoms include
hypoketotic hypoglycemia and Reye-like episodes [1]. It is
estimated that approximately 59% of patients presenting
clinically between 15 to 26 mo of age die during their first
clinical episode [1].
The pathogenesis of the wide range of metabolic dis-
turbances in MCAD deficiency is poorly understood and
certain aspects of patient management are controversial. An
animal model for MCAD deficiency is essential to better
understand the pathogenesis of MCAD deficiency and to
develop better management regimens for human patients. To
gain further insight into the mechanisms of this disease, we
developed a mouse model of MCAD deficiency by gene
targeting in embryonic stem (ES) cells (for reviews [13,14]).
The mutant mice had many relevant features characteristic of
the disease found in human MCAD-deficient patients, along
with some unexpected findings.
Results
Gene Targeting and Generation of MCAD-Deficient Mice
MCAD insertion vector (MCAD IV2) was designed to
undergo gap repair of the 1.3-kb deleted region upon
homologous recombination in 129P2 (129P2/OlaHsd) ES cells
E14–1. Correct targeting of the MCAD locus resulted in a
duplication of exons 8, 9, and 10 and integration of flanking
plasmid and Neo sequences (Figure 1A). The insertion vector
was designed to duplicate exon 8, 9, and 10 at the MCAD
locus. Translation of the duplicated exon 8 region results in
the formation of premature stop codons resulting in
truncation of the MCAD monomer. Specifically, the first
premature stop codon arises after translation of only seven
amino acids from the duplicated exon 8. The resulting MCAD
monomer is missing the C-terminal domain a-helixes that are
responsible for making intersubunit contacts to generate the
functional MCAD homotetramer.
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ES cell clones were screened by PCR (data not shown) and
confirmed by Southern blot analysis. Southern blot analysis
used an exon 10 probe (probe A), not present in the targeting
vector, hybridized to a 13.2-kb band in addition to the 3.1-kb
endogenous band indicating targeted insertion of the vector
at the Acadm locus (Figure 1B). Correctly targeted ES cell
clones were microinjected into B6 (C57BL/6NTac) blastocysts
to generate chimeric mice. Chimeric mice were backcrossed
to both 129P2 and B6 inbred mice to produce MCADþ/ and
eventually MCAD/ mice on a B6/129 mixed background.
The studies described here were conducted exclusively on the
B6/129 mixed background compared with littermate controls
or B6/129 control groups maintained by intercrosses as were
the mutants. Perpetuating this mutation as a congenic mutant
line on the 129P2 background proved impractical. The 129P2
mice were poor breeders as wild-types, and when introduced,
the Acadm mutation was nearly lost on this background
because of the high rate of neonatal death. Because of the
molecular structure of the targeted allele, it proved virtually
impossible to distinguish all three potential genotypes. We
could clearly detect the presence or absence of the targeted
allele, however, whether a particular mouse was MCAD/ or
MCADþ/ could not be determined by Southern blot or PCR
of genomic DNA. Ultimately MCAD/mice were ascertained
by immunoblot analysis of offspring with subsequent perpet-
uation of MCAD/ and MCADþ/þ mice as separate groups.
RNA Analysis
RT-PCR amplification from exon 7 to 11 from total heart
RNA amplified the expected 600-base pair (bp) fragment in
MCADþ/þ and MCADþ/ mice, and a 1.5-kb fragment in
MCAD/mice (data not shown). Sequence analysis of the 1.5-
kb fragment revealed that the amplified fragment consisted
of exon 7 to exon 10 with 280 bp of pGEM plasmid sequence
followed by exons 8–11. Some of the plasmid sequences, along
with the pPGKNEOpA sequence, were deleted from this
spliced mRNA.
Northern blot analysis revealed Acadm was normally ex-
pressed in all tissues analyzed from MCADþ/þ mice with the
most robust expression occurring in brown fat, kidney, heart,
skeletal muscle, and liver with minimal expression in the
brain, white fat, and testes (Figure 2). Interestingly, although
RT-PCR amplified an incorrectly spliced Acadm transcript, no
Acadm transcripts were detected by northern blot analysis
from MCAD/ mice. These results strongly suggest that the
mutant RNA is unstable and degraded rapidly or, alterna-
tively, undergoes nonsense mediated RNA decay.
Liver Enzyme Analyses
Immunoblot analyses of liver homogenates with anti-
MCAD antisera demonstrated that the 42 kDa MCAD
monomer was present in MCADþ/þmice, but not in MCAD/
mice (Figure 3). As a control analysis, anti–short-chain acyl-
CoA dehydrogenase (SCAD) antisera revealed no differences
in levels of expression of SCAD protein between MCADþ/þ and
MCAD/mice (Figure 3).
Enzyme activity was analyzed in mouse liver homogenates
using the electron transport flavoprotein (ETF) reduction
assay with octanoyl-CoA (C8:0) and palmitoyl-CoA (C16:0) as
substrates. MCAD/ mice had a significant reduction in
ability to dehydrogenate octanoyl-CoA and a modest reduc-
tion in activity toward palmitoyl-CoA compared to MCADþ/þ
mice (Table 1). Specifically, the dehydrogenation of octanoyl-
CoA and palmitoyl-CoA substrates were reduced by 75% and
by 30%, respectively, in MCAD/ mice as compared to
MCADþ/þ controls.
Figure 1. Strategy for Disruption of the Mouse Acadm Gene
(A) The MCAD IV2 insertion targeting vector with a deleted 1.3-kb region
encompassing exon 10 and flanking sequences. MCAD IV2 undergoes
gap repair upon homologous recombination at the endogenous Acadm
locus resulting in a duplication of exons 8, 9, and 10 at the disrupted
allele.
(B) Southern blot analysis of EcoRI-digested genomic DNA from ES cells
screened by PCR. Probe A, a DNA fragment consisting of a portion of
exon 10 that is not present in the targeting vector, hybridizes to an
endogenous 3.1-kb fragment and, upon homologous recombination, to
a 13.2-kb fragment. Lane 1 represents a wild-type ES cell line, and Lane 2
and 3 represent targeted ES cell lines.
DOI: 10.1371/journal.pgen.0010023.g001
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Synopsis
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is one of
the most common inherited disorders of metabolism. This defect in
fatty acid oxidation can lead to severe and sometimes fatal disease,
especially in young children because they are unable to tolerate a
fasting episode. Metabolic complications include very low blood
glucose concentrations and generation of toxic by-products. This
disorder can result in sudden infant death. Using a process known as
gene targeting in mouse embryonic stem cells, the authors have
developed a mouse model with the same enzyme deficiency. This
mouse model of MCAD deficiency develops many of the same
disease characteristics found in affected children. The MCAD-
deficient mouse model shows a high rate of newborn loss,
intolerance to cold, and the characteristic biochemical changes in
the blood, tissues, and urine that are very similar to those found in
the human disease counterpart. The MCAD-deficient mouse model
will allow researchers to better understand disease mechanisms so
that new preventive measures or therapies can be developed.
MCAD Gene Disruption in the Mouse
Neonatal Deaths
Significant neonatal mortality was noted in MCAD/ pups.
Although equal numbers of pups were born from MCADþ/þ
and MCAD/ mice, only 41% of MCAD/ mice survived to
weaning as compared to 98% of MCADþ/þmice (Table 1). The
mechanism of neonatal loss remains undetermined. The
MCAD/pups are abandoned more frequently than MCADþ/þ
pups for unknown reasons. They are likely more prone to
hypothermia than MCADþ/þ. Because of the difficulty of
distinguishing the MCAD/ mutants from the MCADþ/
heterozygous pups by molecular analysis due to the insertion
mutation, we could only compare MCADþ/þ 3 MCADþ/þ
matings with MCAD/ 3 MCAD/ matings. Thus, we were
unable to evaluate the pedigrees from heterozygous matings.
Fasting and Cold Intolerance
In order to examine the stress effects of fasting on MCAD-
deficient mice, they were fasted for 24 h prior to analysis.
MCAD/ mice displayed lower serum glucose and elevated
serum free fatty acid levels although neither result was
significant, as compared to MCADþ/þ mice (Table 1).
To determine the effects of cold stress, mice were fasted for
18 h and placed in 4 8C environment for a 3-h period. The
MCAD/ mice were significantly compromised within this
short period of cold stress, some severe enough to result in
fatalities. After 1 h of the cold challenge, the average rectal
temperature of MCAD/mice (n¼5) was 23.4 8C as compared
with 35 8C for MCADþ/þ mice (n ¼ 4). Rectal temperatures
declined to unrecoverable temperatures of 16.7–19.2 8C in
three of the five MCAD/mice. By the end of the 1.5-h mark,
the two surviving MCAD/mice averaged 22.7 8C. In contrast,
all four MCADþ/þ mice survived the 3-h cold stress, ending
with an average rectal temperature of 33.6 8C.
Organic Acid and Acylcarnitine Analysis
Urine organic acid analysis revealed that MCAD/ mice
developed an organic acid profile similar to MCAD-deficient
human patients. Specifically, when fasted for 18 h, MCAD/
mice developed significantly elevated concentrations of
adipic, suberic, and sebacic acids and hexanoylglycine as
compared to MCADþ/þ controls, which showed trace to no
detectable amounts of the same organic acids (Table 1).
Adipic acid is not specific to MCAD deficiency. We also
evaluated b-hydroxybutyric and acetoacetic concentrations
and found no significant differences between MCAD geno-
types (data not shown).
Comparison of MCADþ/þ and MCAD/ mice revealed no
significant differences in total serum carnitine concentra-
tions between MCADþ/þ and MCAD/ mice, but MCAD/
mice had a 5- to 6-fold elevation of serum decenoylcarnitine
evident in the acylcarnitine profile (Figure 4A). Bile acylcar-
nitine analysis revealed a similar acylcarnitine pattern as in
serum (Figure 4B). However, the acylcarnitine profiles of the
MCAD/ mice are different from those of human MCAD-
deficient patients (Figure 4C). Human patients present with
elevated levels of C6, C8, and C10:1 acylcarnitines, as did the
mutant mice; however, the predominant peak was C8
acylcarnitine in humans, whereas in the mouse it was C10:1
acylcarnitine.
Histopathology
Complete histopathologic examination of one group of
mutant and MCADþ/þ control mice after a 24-h fast
demonstrated diffuse microvesicular and macrovesicular
hepatic steatosis in 6–8-wk-old MCAD/ mice whereas
Figure 3. Immunoblots of Liver Homogenates from MCADþ/þ and MCAD/ Mice
These were probed with anti-MCAD antibody or anti-SCAD antibody. Homozygous MCAD/mice had no detectable MCAD protein. MCAD protein is
only detectable under the MCAD protein–spiked (positive control) lane. As a control analysis, liver homogenates probed with anti-SCAD antibody
revealed that SCAD protein was present in both MCADþ/þ and MCAD/mice. No MCAD positive-control protein is detected by anti-SCAD antibodies
(MCAD lane). mw, molecular weight standards.
DOI: 10.1371/journal.pgen.0010023.g003
Figure 2. Northern Blot Analysis from MCAD/ (n¼ 2) and MCADþ/þ (n¼
2) Mice
Acadm message was detected from the heart, liver, brown fat, brain,
kidney, and muscle (and white fat and testes, data not shown) of only
MCADþ/þ mice. Most robust expression occurred in brown fat, kidney,
heart, and skeletal muscle. MCAD/mice had no detectable message in
all tissues examined.
DOI: 10.1371/journal.pgen.0010023.g002
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MCADþ/þmice had no histologic changes (Figure 5A and 5B).
In another group of 4-wk-old MCADþ/þ and MCAD/ mice
fasted for 24-h, there were minimal to no abnormalities in all
organs evaluated. Only the older MCAD/ mice, therefore,
demonstrated hepatic steatosis. In addition, we found
sporadic cardiac lesions in multiple MCAD/ mice.
In one example, an MCAD/mouse had diffuse cardiomy-
opathy with chronic active multifocal myocyte degeneration
and necrosis (Figure 5C and 5D). Changes in degenerating
myocytes included swelling, pale staining, and, in portions of
the sarcoplasm, replacement of myofibrils with finely gran-
ular eosinophilic material. Nuclei of affected myocytes were
large, pale, and vesicular and had prominent nucleoli. In the
most severely affected areas, there was loss of myocytes
accompanied by fibrosis. In the wall of the aorta at the base of
the heart there was multifocal degeneration of the elastic
tissue, accompanied by multifocal collections of globular
translucent yellow-brown pigment interpreted to be ceroid/
lipofuscin. Similar deposits were scattered within adjacent
adipose tissue.
Discussion
Successfully targeting Acadm produced a mouse model for
MCAD deficiency with features that mimic the clinical,
biochemical, and pathologic phenotype found in human
patients. MCAD-deficient patients have abnormal plasma and
urine metabolites associated with the medium chain–length
enzyme specificity. MCAD-deficient patients [15] often dis-
play a characteristic urinary hexanoylglycine peak, as was
seen in MCAD/ mice. Acylcarnitine analysis indicated,
however, mouse MCAD is more active toward longer chain
substrates than the human MCAD enzyme. This finding is
similar to that seen with very long-chain acyl-CoA dehydro-
genase (VLCAD) where mouse VLCAD is most active toward
C16 acyl-substrates as compared to human VLCAD with the
most enzymatic activity toward C14 acyl-substrates [16].
ETF reduction assays of liver homogenates were performed
to characterize the MCAD/ mice at the enzymatic level.
MCAD/ mice had a significantly reduced ability to dehy-
drogenate C8-CoA, as is the case in human patients where
MCAD activity is reduced to near zero with C8-CoA . This was
less so with palmitoyl-CoA (C16:0). Because there was clearly
no MCAD antigen detected in MCAD/ mice, the residual
dehydrogenase activity measured with these two substrates
must represent the activity of other chain length–specific
acyl-CoA dehydrogenases.
A high degree of neonatal mortality in MCAD/mice was a
striking observation and appears to be analogous to the
patterns of clinical episodes and mortality in MCAD-deficient
patients. MCAD/ mice exhibited significant neonatal mor-
tality with approximately 60% of the MCAD/ pups dying
prior to weaning at 3 wk of age. Human patients present with
hypoglycemia, hypoketonemia, and nonketotic organic acidu-
ria precipitated by fasting, most frequently during the first 24
mo in life [1]. It is likely that neonatal MCAD/ pups are
manifesting sensitivity to fasting with decompensation in a
short period of time if maternal milk is not ingested. In
contrast, no mortality was noted in adult MCAD/ mice
unless challenged with cold stress and fasting. Under cold
challenge conditions, however, MCAD/mice were unable to
maintain body temperature. Brown fat is predominantly
responsible for thermogenesis and normally expresses high
levels of Acadm mRNA.
The microvesicular and macrovesicular hepatic steatosis
seen in fasted MCAD/ mice is consistent with the primary
pathological finding seen in human MCAD patients with
fasting stress. Sporadic cardiac lesions in MCAD/ mice,
however, were an interesting and unexpected finding. The
diffuse cardiomyopathy with multifocal myocyte degenera-
tion and necrosis observed in MCAD/ mice has not been
reported in human MCAD patients, however, cardiac
arrhythmias and dysfunction have been reported in MCAD-
deficient patients [17, 18]. Interestingly, cardiomyopathy has
been observed in VLCAD deficiency [19] and other disorders
of long chain fat metabolism such as severe CPT-1 and -2
deficiencies [1]. Thus it is tempting to relate the cardiac
problems in the mouse to the apparent broader range of
substrate utilization of mouse MCAD. The inconsistent liver
and cardiac lesions in these mice is analogous with the
significant inter- and intrafamilial phenotypic heterogeneity
seen in MCAD deficiency in humans [1,20].
In comparisons with our experiences with the other mouse
models for acyl-CoA dehydrogenase deficiencies, the overall
phenotype of MCAD/mice is less severe than that found in
LCAD/ mice, yet more pronounced than the VLCAD/ or
SCAD/ mouse models [16,21,22]. All of these mutants are
cold intolerant and display varying degrees of fatty changes in
liver, heart, and kidney. LCAD/ mice show more sponta-
neous deaths and gestational losses than the other deficien-
cies [21]. The significant neonatal mortality in MCAD/mice
is distinctive from these other mouse models suggesting a
greater degree of sensitivity to fasting intolerance. The
phenotypes of both the VLCAD/ and SCAD/ mice are
relatively mild if the animals are not cold stressed [16,22]. The
MCAD-deficient mouse offers new insights into the patho-
genesis of mitochondrial b-oxidation deficiencies and will
provide a robust tool to better understand the role of fatty
acids in other relevant diseases.
Table 1. Characteristics of MCAD-Deficient Mice
Characteristic Substrate MCADþ/þ MCAD/ p-Value
ETF reduction
assay, mU/mga
Octanoyl-CoA 32.3 6 5.5 7.74 6 0.84 p , 0.001
Palmitoyl-CoA 21.3 6 10.6 13.1 6 0.70 p ¼ 0.12
Average litter
sizeb
Pups born 6.38 5.80 p ¼ 0.35
Pups weaned 6.25 2.40 p , 0.01
Serum glucose and
free fatty acid
concentrationsc
Glucose, mg/dl 205 6 65 150 6 65 p ¼ 0.24
Free fatty acids,
mEq/L
0.50 6 0.14 0.92 6 0.35 p ¼ 0.054
Urinary organic
acids, nmol/mmol
creatinined
Adipic 48.5 6 46.0 180 6 25.5 p , 0.001
Suberic 4.43 6 4.49 14.8 6 3.28 p ¼ 0.005
Sebacic 0.32 6 0.63 1.55 6 0.770 p ¼ 0.036
Hexanoylglycinee 1.77 6 0.97 61.4 6 7.62 p , 0.001
Values given are mean 6 SD.
aMCADþ/þ n ¼ 5 and MCAD/ n ¼ 5.
bMCADþ/þ n ¼ 8 litters and MCAD/ n ¼ 10 litters.
cMCADþ/þ n ¼ 5 and MCAD/ n ¼ 6.
dMCADþ/þ n ¼ 4 and MCAD/ n ¼ 5.
eExpressed as a ratio relative to the internal standard.
DOI: 10.1371/journal.pgen.0010023.t001
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Figure 4. Acylcarnitine Analyses
(A) Serum acylcarnitine analysis of MCADþ/þ (n¼ 4) and MCAD/ mice (n¼ 4)
There are significant elevations in acylcarnitine species as indicated in MCAD/mice. Values shown are mean values6 standard deviation (SD). Asterisk
indicates p , 0.002 and z indicates p , 0.01.
(B) There are significant elevations in bile acylcarnitines of the same mice shown in (A) as indicated. Values shown are mean values 6 SD. Asterisk
indicates p , 0.001.
(C) Bile acylcarnitine profile of an MCAD/mouse compared to a human patient with MCAD deficiency. Internal standards are indicated by an asterisk.
DOI: 10.1371/journal.pgen.0010023.g004
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Materials and Methods
Construction of MCAD targeting vector. A neomycin resistance
gene cassette [23] was subcloned into the SalI site of pGEM11Zf(þ).
The plasmid was digested with EcoRI and the overhangs were filled
with Klenow enzyme. Subsequent ligation of the blunt ends
recircularized the vector and destroyed the EcoRI site within the
polylinker of the pGEMl1Zf(þ) plasmid. Next, an 8-kb Acadm genomic
fragment spanning exons 8, 9, and 10 and flanking intron sequences,
originally obtained from a Lambda FIXII 129Sv mouse genomic
library [24,25], was directionally cloned into the NotI and XhoI sites
of pGEM11Zf(þ). The vector was digested with BamHI and EcoRI to
remove a 1.3-kb BamHI/EcoRI genomic fragment containing exon 10
and flanking intron sequences. The digested vector, without the 1.3-
kb BamHI/EcoRI genomic fragment, was purified by gel purification
and recircularized by ligation using three oligonucleotides: 59-
AATTGTCGACA-39; 59GATCGTCGACA-39; and 59-TCGATGTC-
GAC-39. The recircularized vector, resulting from the ligation of
the long arm to the short arm of homology, contained a unique SalI
site where the 1.3-kb exon 10 region was deleted.
Generation of MCAD-deficient mice. The Acadm insertion vector
was linearized by SalI digestion, the site of the 1.3-kb genomic
fragment deletion, and electroporated into E14–1 ES cells (a kind gift
from R. Kuhn), derived from 129P2 mice. Correctly targeted Acadm
insertion vector was designed to undergo gap repair of the 1.3-kb
deletion upon double stranded–break repair [26] during homologous
recombination. Southern blot analysis was conducted to confirm
homologous recombination. Genomic DNA from G418 resistant ES
colonies was digested with EcoRI, electrophoresed, blotted, and
probed with an 850-bp probe (probe A) generated by PCR from
Acadm exon 10 to intron 10. This DNA fragment is not present within
Acadm insertion vector and was expected to hybridize to a 13.2-kb
genomic DNA fragment upon homologous recombination. Correctly
targeted ES cell clones were microinjected into B6 blastocysts to
generate chimeric mice. Chimeric mice were subsequently back-
crossed to B6 and 129P2 mice to produce gene-targeted mice
AcadmtmUab1/þ (MCADþ/) and eventually AcadmtmUab1/tm1Uab MCAD/
(B6;129) mice. Mice were negative for mouse pathogens based on
serological assays for ten different viruses, aerobic bacterial cultures
of nasopharynx and cecum, examinations for endo- and ectopar-
asites, and histopathology of all major organs.
RNA analysis. Total RNA was isolated from the heart of 30 day old
MCADþ/þ, MCADþ/, and MCAD/mice by standard techniques using
guanidinium thiocyanate method [27]. Reverse transcription was
performed using random oligonucleotides as recommended by the
manufacturer (Clontech, Mountain View, California, United States).
PCR was subsequently performed using oligonucleotides specific to
exon 7 and exon 11 of Acadm. PCR amplifications were performed as
described above. PCR fragments were subsequently sequenced after
subcloning into pGEM-T Easy vector (Promega, Madison, Wisconsin,
United States).
In order to determine the extent of Acadm mRNA expressed from
the MCAD/mice, northern blot analysis was performed. Total RNA
was isolated from heart, liver, brown fat, brain, kidney, skeletal muscle,
white fat, and testes of 3-mo-oldMCADþ/þandMCAD/mice using the
Ultraspec RNA Isolation Kit (BIOTEX Laboratories, Inc., Houston,
Texas, United States) as per manufacturer’s protocol. Ten lg of total
RNA from each sample was loaded onto a 0.8% agarose-formaldehyde
gel, transferred to nitrocellulose filter (Hybond N; GE Healthcare
Amersham Biosciences Corp., Piscataway, New Jersey, United States),
and hybridized with 32P-radiolabeled full-length mouse Acadm cDNA
probe using standard procedures [28]. Hybridizations were performed
under highly stringent conditions (42 8C in 23 SSC, 50% formamide,
10% dextran sulfate, 53 Denhardt’s reagent, 1% SDS, and salmon
spermDNA) for 18 h. The hybridized filter was washed two times in 43
SSC, 0.1% SDS and two times in 23SSC; 0.1% SDS at 55 8C for 1 h. The
filter was exposed to autoradiographic film (Hyperfilm MP; GE
Healthcare Amersham Biosciences, Piscataway, New Jersey, United
States). Replicate agarose-formaldehyde gels were stained by ethidium
bromide to verify equal RNA loading.
Immunoblot analysis of MCAD protein. To evaluate the quantity
of MCAD protein in mouse tissue, liver samples from 6–8-wk-old
MCADþ/þ (n¼ 1) and MCAD/ (n¼ 3) mice were immediately frozen
in liquid nitrogen and stored at 80 8C. For analysis, tissue was
Figure 5. Histopathology of MCADþ/þ and MCAD/ Mice
(A) MCADþ/þ mice had no evidence of hepatic steatosis following a 24-h fast. Liver section with Oil-Red O stain.
(B) Hepatosteatosis in MCAD/ mouse following a 24-h fast. Oil-Red O stained liver sections revealed severe and diffuse microvesicular and
macrovesicular hepatic steatosis in MCAD/ mice.
(C and D) Diffuse cardiomyopathy with chronic active multifocal myocyte degeneration and necrosis in MCAD/ mice.
DOI: 10.1371/journal.pgen.0010023.g005
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homogenized and lysed in RIPA buffer (13 PBS, 1% Nonidet P-40,
0.5% sodium deoxycholate, and 1% SDS) with 10% glycerol and
Complete Protease Inhibitor, (Roche Diagnostics Corporation,
Indianapolis, Indiana, United States), 1 mM of phenylmethylsulfo-
nylfluoride, and 1 mM of sodium orthovanadate. Lysates were
quantified by Bradford BCA protein assay (Bio-Rad, Hercules,
California, United States). Protein lysates were denatured, separated
in 8% SDS-PAGE, and transferred overnight onto a 0.45 lm
nitrocellulose membrane (Schleicher and Schuell, Keene, New
Hampshire, United States). After blocking with 5% nonfat milk in
phosphate-buffered saline with 0.1% Tween-20, the membrane was
immunoblotted overnight at 4 8C with 1:500 dilution of an anti-
MCAD antibody. Blots were incubated in anti-mouse IgG HRP-
conjugated secondary antibody for 2–4 h at room temperature using
standard procedures and developed by chemiluminiscence (Renais-
sance, NEN Lifesciences Products, Boston, Massachusetts, United
States).
Liver enzyme activity. In order to evaluate MCAD activity in mice,
liver homogenates were prepared from MCADþ/þ (n¼5) and MCAD/
mice (n¼5). The sensitive and highly specific anaerobic ETF reduction
assay was used on tissue extracts with octanoyl-CoA (C8) and palmitoyl-
CoA (C16) as substrate as previously described [29].
Fasting and cold challenge. Eight-wk-old MCADþ/þ and MCAD/
mice were fasted for 18 h (cold tolerance experiments) or 24 h (serum
glucose, free fatty acid, organic acid, and carnitine experiments) prior
to analysis. Glucose concentration was measured in 10 ll sera using an
Ektachem DT II system (Johnson and Johnson Clinical Diagnostics,
Rochester, New York, United States). Total non-esterified fatty acids
(NEFA) weremeasured by an enzymatic, colorimetricmethod (‘‘NEFA-
C’’ reagents, Wako Diagnostics, Richmond, Virginia, United States).
The assay was modified to accommodate a reduced sample size (10 ll)
and use of a microplate reader for measurement of optical density at
550 nm. Urine organic acid analyses were performed using gas
chromatography-mass spectroscopy as previously described [22,30],
except tetracosane (C24; Sigma, St. Louis, Missouri, United States) was
used as the internal standard, and quantitative determinations were
made based on comparison with synthetic calibration standards.
Acylcarnitine analyses in serum and bile were conducted using
electrospray tandem mass spectrometry [31,32].
Histopathology. Twelve mice were examined for gross and his-
tologic abnormalities, including one male and one female MCAD/
mouse 18-mo-old, one male and one female MCADþ/þ mouse 6-mo-
old, two male and two female MCAD/mice 4-wk-old, and two male
and two female MCADþ/þ mice 4-wk-old. Kidney, spleen, pancreas,
liver, brain, heart, testicles, ovaries, and skeletal muscle were fixed by
immersion in buffered 10% formalin, processed routinely for
paraffin sectioning, sectioned at 5 lm, and stained with hematoxylin
and eosin. Frozen liver sections were prepared using standard
methods and sections were stained with Oil-red-O. Slides were
examined without knowledge of genotype or age. Other mice were
examined because of sporadic clinical disease. Those with visible
cardiac enlargement were evaluated for cardiac lesions.
Statistical analyses. Results between groups were tested for
statistical significance using Student’s t-test. A p , 0.05 was set as
significant.
Supporting Information
Accession Number
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession
number for the mouse gene Acadm is U07159.
Acknowledgments
We thank Sushama Varma for technical assistance. This research was
supported by the University of Alabama at Birmingham (UAB)
Comprehensive Cancer Center (Oligonucleotide and Transgenic
Animal Shared Facilities) grant P30-CA13148, UAB Musculoskeletal
Disease and Arthritis Center (Gene Targeting Core Facility) grant
P60-AR20614, UAB Clinical Nutrition Research Center grant P30-
DK-56336, and by National Institutes of Health grants R01-RR02599
(PAW), T32-RR-07003 (RJT), K01-RR00129 (RJT), RO1-DK45482 (JV),
and DK54936 (JV).
Competing interests. The authors have declared that no competing
interests exist.
Author contributions. RJT, JV, PR, DM, and PAW conceived and
designed the experiments. RJT, DAH, LT, JV, PR, DM, JDS, and
PAW performed the experiments. RJT, DAH, LT, JV, JDS, PR, DM,
TRS, and PAW analyzed the data and contributed reagents/
materials/analysis tools. RJT, JV, PR, DM, TRS, JDS, and PAW wrote
the paper.
References
1. Rinaldo P, Matern D, Bennett MJ (2002) Fatty acid oxidation disorders.
Annu Rev Physiol 64: 477–502.
2. Matsubara Y, Kraus JP, Ozasa H, Glassberg R, Finocchiaro G, et al. (1987)
Molecular cloning and nucleotide sequence of cDNA encoding the entire
precursor of rat liver medium chain acyl coenzyme A dehydrogenase. J Biol
Chem 262: 10104–10108.
3. Kelly DP, Kim JJ, Billadello JJ, Hainline BE, Chu TW, et al. (1987)
Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA
and its expression in enzyme-deficient human tissue. Proc Natl Acad Sci
U S A 84: 4068–4072.
4. Ikeda Y, Keese SM, Fenton WA, Tanaka K (1987) Biosynthesis of four rat
liver mitochondrial acyl-CoA dehydrogenases: In vitro synthesis, import
into mitochondria, and processing of their precursors in a cell-free system
and in cultured cells. Arch Biochem Biophys 252: 662–674.
5. Kolvraa S, Gregersen N, Christensen E, Hobolth N (1982) In vitro fibroblast
studies in a patient with C6-C10-dicarboxylic aciduria: Evidence for a
defect in general acyl-CoA dehydrogenase. Clin Chim Acta 126: 53–67.
6. Stanley CA, Hale DE, Coates PM, Hall CL, Corkey BE, et al. (1983) Medium-
chain acyl-CoA dehydrogenase deficiency in children with non-ketotic
hypoglycemia and low carnitine levels. Ped Res 17: 877–884.
7. Rhead WJ, Amendt BA, Fritchman KS, Felts SJ. Dicarboxylic aciduria:
Deficient [1-14C] octonoate oxidation and medium-chain acyl-CoA dehy-
drogenase in fibroblasts. Science 221: 73–75.
8. Coates PM (1992) Historical perspective of medium-chain acyl-CoA dehy-
drogenase deficiency: A decade of discovery. Prog Clin Biol Res 375: 409–423.
9. Matsubara Y, Narisawa K, Tada K (1992) Medium-chain acyl-CoA
dehydrogenase deficiency: Molecular aspects. Eur J Pediatr 151: 154–159.
10. Ding JH, Bross P, Yang BZ, Lafolla AK, Millington DS, et al. (1992) Genetic
heterogeneity in MCAD deficiency: Frequency of K329E allele and
identification of three additional mutant alleles. In: Coates PM, Tanaka
K, editors. New developments in fatty acid oxidation. New York: Wiley-Liss.
pp. 479–488.
11. Workshop on Molecular Aspects of MCAD Deficiency (1992) Mutations
causing medium-chain acyl-CoA dehydrogenase deficiency: A collaborative
compilation of the data from 172 patients. In: Coates PM, Tanaka K,
editors. New developments in fatty acid oxidation. New York: Wiley-Liss.
pp. 499–506.
12. Matern D, Rinaldo P (2003) Medium-chain acyl-coenzyme A dehydrogenase
deficiency. Available:http://www.geneclinics.org/servlet/access?db¼
geneclinics&site¼gt&id¼8888891&key¼YpeEakmrXPZ3i&gry¼&fcn¼y&
fw¼nYYD&filename¼/profiles/mcad/index.html. Accessed 21 July 2005.
13. Capecchi MR (1989) Altering the genome by homologous recombination.
Science 244: 1288–1292.
14. Koller BH, Smithies O (1992) Altering genes in animals by gene targeting.
Annu Rev Immunol 10: 705–730.
15. Rinaldo P, O’Shea JJ, Coates PM, Hale DE, Stanley CA, et al. (1988) Medium-
chain acyl-CoA dehydrogenase deficiency. Diagnosis by stable-isotope
dilution measurement of urinary n-hexanoylglycine and 3-phenylpropio-
nylglycine. N Engl J Med 319: 1308–1313.
16. Cox KB, Hamm DA, Millington DS, Matern D, Vockley J, et al. (2001)
Gestational, pathologic and biochemical differences between very long-
chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA
dehydrogenase deficiency in the mouse. Hum Mol Genet 10: 2069–2077.
17. Feillet F, Steinmann G, Vianey-Saban C, de Chillou C, Sadoul N, et al.
(2003) Adult presentation of MCAD deficiency revealed by coma and severe
arrythmias. Intensive Care Med 29: 1594–1597.
18. Maclean K, Rasiah VS, Kirk EP, Carpenter K, Cooper S, et al. (2005)
Pulmonary haemorrhage and cardiac dysfunction in a neonate with
medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Acta Paediatr
94: 114–116.
19. Vianey-Saban C, Divry P, Brivet M, Nada M, Zabot MT, et al. (1998)
Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency:
Clinical characteristics and diagnostic considerations in 30 patients. Clin
Chim Acta 269: 43–62.
20. Duran M, Hofkamp M, Rhead WJ, Saudubray JM, Wadman SK (1986)
Sudden child death and ‘healthy’ affected family members with medium-
chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics 78: 1052–1057.
21. Kurtz DM, Rinaldo P, Rhead WJ, Tian L, Millington DS, et al. (1998)
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene
reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci U S A 95:
15592–15597.
22. Wood PA, Amendt BA, Rhead WJ, Millington DS, Inoue F, et al. (1989)
Short-chain acyl-coenzyme A dehydrogenase deficiency in mice. Pediatr
Res 25: 38–43.
PLoS Genetics | www.plosgenetics.org August 2005 | Volume 1 | Issue 2 | e230211
MCAD Gene Disruption in the Mouse
23. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption
of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693–702.
24. Tolwani RJ, Farmer SC, Wood PA (1994) Molecular cloning and character-
ization of the mouse medium-chain acyl-CoA dehydrogenase cDNA.
Genomics 23: 247–249.
25. Tolwani RJ, Farmer SC, Johnson KR, Davisson MT, Kurtz DM, et al. (1996)
Structure and chromosomal location of the mouse medium-chain acyl-CoA
dehydrogenase-encoding gene and its promoter. Gene 170: 165–171.
26. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW (1983) The double-
strand-break repair model for recombination. Cell 33: 25–35.
27. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Bio-
chem 162: 156–159.
28. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: A laboratory
manual, 2nd ed. Cold Spring Harbor (New York): Cold Spring Harbor
Laboratory. 1,659 p.
29. Mohsen AW, Vockley J (1995) Identification of the active site catalytic
residue in human isovaleryl-CoA dehydrogenase. Biochemistry 34: 10146–
10152.
30. Wood PA, Armstrong D, Sauls D, Davisson MT (1988) Screening mutant
mice for inborn errors of metabolism. Lab Anim Sci 38: 15–19.
31. Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn
errors of metabolism from blood spots by acylcarnitines and amino acids
profiling using automated electrospray tandem mass spectrometry. Pediatr
Res 38: 324–331.
32. Rinaldo P, Hahn SH, Matern D (2005) Inborn errors of amino acid, organic
acid, and fatty acid metabolism. In: Burtis CA, Ashwood ER, Bruns D,
editors. Tietz textbook of clinical chemistry, 4th ed. St. Louis (Missouri):
Elsevier. pp. 2207–2247.
PLoS Genetics | www.plosgenetics.org August 2005 | Volume 1 | Issue 2 | e230212
MCAD Gene Disruption in the Mouse
